

July 23, 2013

ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2013 Financial Results

— Webcast of presentation at upcoming investor conference also announced —

WALTHAM, Mass.--(BUSINESS WIRE)-- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) antibody-drug conjugate technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, August 2, 2013, to discuss ImmunoGen's financial results for the three-month period and fiscal year ended June 30, 2013. Management also will provide guidance for its fiscal year ending June 30, 2014 and an update on the Company.

To access the live call by phone, dial 913-312-0836. Passcode: 4198948. The call also may be accessed through the Investor Information section of the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through August 16, 2013.

ImmunoGen's presentation at the Wedbush 2013 Life Sciences Management Access Conference on August 14, 2013 at 12:45 pm ET also will be webcast. It will be accessible live through the Company's website as described above, with a replay available for approximately one week.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's TAP technology uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells. Ten TAP compounds are now in the clinic, of which three are wholly owned by the Company. The most advanced compound using ImmunoGen's TAP technology, Kadcyla™, has been approved for marketing in the US and Switzerland, and is undergoing regulatory review in the European Union and Japan. Kadcyla is being commercialized in the US by Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.

Kadcyla™ is a trademark of Genentech.

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com

or
For Media:
The Yates Network
Barbara Yates, 781-258-6153

Source: ImmunoGen, Inc.

News Provided by Acquire Media